Influenza Virus Patents (Class 424/206.1)
-
Patent number: 9028838Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: March 4, 2013Date of Patent: May 12, 2015Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Patent number: 9017694Abstract: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: October 4, 2012Date of Patent: April 28, 2015Assignee: MedImmune, LLCInventors: Hong Jin, Zhongying Chen
-
Patent number: 9011874Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: November 22, 2010Date of Patent: April 21, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
-
Patent number: 9005621Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: GrantFiled: July 3, 2014Date of Patent: April 14, 2015Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Patent number: 9005632Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: July 20, 2012Date of Patent: April 14, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy C. Jones, Joseph N. Brewoo
-
Patent number: 8999352Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: November 23, 2011Date of Patent: April 7, 2015Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 8986987Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.Type: GrantFiled: October 17, 2011Date of Patent: March 24, 2015Assignee: Intervet Inc.Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
-
Patent number: 8980279Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.Type: GrantFiled: July 27, 2012Date of Patent: March 17, 2015Assignee: Qu BiologicsInventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Publication number: 20150056235Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: October 6, 2014Publication date: February 26, 2015Inventors: PATTI CYNTHIA CRAWFORD, PAUL J. GIBBS, EDWARD J. DUBOVI, RUBEN OMAR DONIS, JACQUELINE KATZ, ALEXANDER I. KLIMOV, NALLAKANNU P. LAKSHMANAN, MELISSA ANNE LUM, DANIEL GHISLENA EMIEL GOOVAERTS, MARK WILLIAM MELLENCAMP, NANCY J. COX, WILLIAM L. CASTLEMAN
-
Patent number: 8956618Abstract: Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.Type: GrantFiled: January 21, 2011Date of Patent: February 17, 2015Assignees: The Texas A&M University System, The Board of Trustees of the University of ArkansasInventors: Luc Berghman, Walter Bottje, Billy Hargis, Sherryll Layton
-
Patent number: 8945904Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.Type: GrantFiled: May 20, 2011Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Heidi Trusheim, Peter Mason, Michael Franti, Bjoern Keiner, Melissa Sackal, Juerg Hunziker, Francois Natt, David Morrissey
-
Patent number: 8940517Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.Type: GrantFiled: April 18, 2012Date of Patent: January 27, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Michael Graninger, Martin Kaliwoda
-
Patent number: 8916160Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.Type: GrantFiled: February 14, 2012Date of Patent: December 23, 2014Assignee: Theraclone Sciences, Inc.Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
-
Publication number: 20140370032Abstract: The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza A hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza A subtypes of subtype group 1 and 2, to vaccines and uses thereof.Type: ApplicationFiled: August 27, 2012Publication date: December 18, 2014Applicant: UNIVERSITAT ZURICHInventors: Lars Hangartner, Arkadiusz Wyrzucki
-
Patent number: 8900590Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.Type: GrantFiled: August 12, 2011Date of Patent: December 2, 2014Assignee: Theraclone Sciences, Inc.Inventors: Ole Olsen, Christina L. Boozer, Andres G. Grandea, III
-
Publication number: 20140341974Abstract: A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.Type: ApplicationFiled: March 17, 2014Publication date: November 20, 2014Inventors: Aryo Sorayya, Mitra Mosharraf, Rajiv Nayar
-
Publication number: 20140341948Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: May 22, 2014Publication date: November 20, 2014Applicant: Icahn School of Medicine at Mount SinaiInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Patent number: 8883479Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.Type: GrantFiled: November 25, 2009Date of Patent: November 11, 2014Assignee: Baxter Healthcare SAInventors: Brigitte Krenn, Markus Wolschek, Julia Romanova, Andrej Egorov, Sabine Nakowitsch
-
Patent number: 8883481Abstract: A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.Type: GrantFiled: October 20, 2010Date of Patent: November 11, 2014Assignee: Novartis AGInventors: Philip Dormitzer, Björn Keiner, Pirada Suphaphiphat, Michael Franti, Peter Mason, Jennifer Uhlendorff, Mikhail Matrosovich
-
Patent number: 8883171Abstract: Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.Type: GrantFiled: September 9, 2011Date of Patent: November 11, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Brendan M. Giles
-
Publication number: 20140328875Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
-
Patent number: 8877209Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.Type: GrantFiled: May 23, 2011Date of Patent: November 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Patent number: 8877210Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: January 15, 2014Date of Patent: November 4, 2014Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8852595Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: GrantFiled: October 10, 2013Date of Patent: October 7, 2014Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Patent number: 8834892Abstract: Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system.Type: GrantFiled: August 22, 2011Date of Patent: September 16, 2014Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Baik Lin Seong, Yo Han Jang, Kwang Hee Lee, Young Ho Byun
-
Patent number: 8834881Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: GrantFiled: March 7, 2013Date of Patent: September 16, 2014Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Patent number: 8809290Abstract: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-?, IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process.Type: GrantFiled: April 1, 2011Date of Patent: August 19, 2014Assignee: Multicell Immunotherapeutics, Inc.Inventors: Adrian Bot, Lilin Wang, Dan Joseph Smith, William Joseph Phillips, Jr., Luis A. Dellamary
-
Publication number: 20140220075Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: MEDIMMUNE, LLCInventors: Enrich HOFFMAN, Hong Jin, Bin Lu, Greg Duke, George Kemble
-
Patent number: 8784838Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.Type: GrantFiled: March 15, 2013Date of Patent: July 22, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
-
Patent number: 8771703Abstract: The present invention provides a recombinant soluble trimeric hemagglutinin (rHA) protein comprising a hemagglutinin ectodomain and an oligomerization domain. The rHA is produced as a soluble homotrimer, and may further comprises a signal peptide and/or an endoplasmic reticulum (ER) retention signal. The invention is also directed to nucleic acids encoding the rHA of the invention, as well as vectors and chimeric constructs comprising the nucleic acid. Methods of producing the rHA are also provided. The rHA described herein may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: GrantFiled: July 7, 2009Date of Patent: July 8, 2014Assignee: Medicago Inc.Inventors: Manon Couture, Nathalie Landry, Louis-Philippe Vezina, Michéle Dargis
-
Patent number: 8765139Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: September 30, 2011Date of Patent: July 1, 2014Assignee: Icahn School of Medicine at Mount SinaiInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Patent number: 8765136Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: April 28, 2010Date of Patent: July 1, 2014Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
-
Patent number: 8747861Abstract: The present invention relates to multimeric multi-epitope peptide-based vaccines. In particular, the present invention relates to the use of multimeric multi-epitope peptide-based vaccines eliciting protective immunity to influenza.Type: GrantFiled: August 3, 2008Date of Patent: June 10, 2014Assignee: BiondVax Pharmaceuticals Ltd.Inventors: Tamar Ben-Yedidia, Yossi Singer
-
Patent number: 8741301Abstract: The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.Type: GrantFiled: December 3, 2009Date of Patent: June 3, 2014Assignee: Baxter Healthcare SAInventors: Thomas Muster, Andrej Egorov, Markus Wolschek
-
Publication number: 20140134208Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.Type: ApplicationFiled: September 26, 2013Publication date: May 15, 2014Applicant: MEDIMMUNE, LLCInventors: Erich HOFFMANN, Hong JIN, George KEMBLE, Zhongying CHEN
-
Patent number: 8722059Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.Type: GrantFiled: August 19, 2011Date of Patent: May 13, 2014Assignee: MedImmune, LLCInventors: Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble
-
Patent number: 8709780Abstract: The present invention aims to provide a method which enables efficient removal of impurities such as the host proteins from an influenza virus culture liquid by a simple operation, allowing separation and purification of an influenza virus antigen. The method of the present invention for producing a purified influenza virus antigen comprises the step of treating a sample containing an influenza virus with a surfactant, the step of bringing the sample after the treatment into contact with hydroxyapatite in the presence of the surfactant, and the step of recovering a hydroxyapatite-non-adsorbed fraction.Type: GrantFiled: September 29, 2009Date of Patent: April 29, 2014Assignee: Denka Seiken Co., Ltd.Inventors: Koichi Takahashi, Kazuaki Maeda, Noriyuki Izutani, Shinichi Yanagi, Yukiko Nakashima
-
Patent number: 8691238Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.Type: GrantFiled: December 18, 2009Date of Patent: April 8, 2014Assignee: Baxter Healthcare SAInventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
-
Patent number: 8691239Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: September 25, 2013Date of Patent: April 8, 2014Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8685410Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: February 14, 2013Date of Patent: April 1, 2014Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8685409Abstract: There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses.Type: GrantFiled: November 1, 2012Date of Patent: April 1, 2014Assignee: Mogam Biotechnology Research InstituteInventors: Jin-Won Youn, Ji-Sun Kwon, Jung-Soon Yoon, Yeon-Jung Kim
-
Patent number: 8678184Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.Type: GrantFiled: December 3, 2010Date of Patent: March 25, 2014Assignee: Novartis AGInventors: Gottfried Kraus, Robert Eskes
-
Patent number: 8673613Abstract: The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection.Type: GrantFiled: June 18, 2008Date of Patent: March 18, 2014Assignee: Medimmune, LLCInventors: Hong Jin, Zhongying Chen
-
Patent number: 8673285Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for modulating the immune response of a subject. Other aspects of the invention concern methods for modulating the immune response of a subject by the use of the conjugate, complexes comprising, the sphingoid-polyalkylamine conjugate in combination with a biologically active molecule capable of modulating an immune response of a subject, compositions comprising the conjugate as well as kits making use of said conjugate. A preferred conjugate according to the invention is N palmitoyl D-erythro sphingosyl 1 carbamoyl spermine.Type: GrantFiled: June 17, 2004Date of Patent: March 18, 2014Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Biolab Ltd.Inventors: Yechezkel Barenholz, Aviva Joseph, Eliezer Kedar
-
Patent number: 8669047Abstract: The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.Type: GrantFiled: July 21, 2011Date of Patent: March 11, 2014Assignee: Theranos, Inc.Inventors: Elizabeth A. Holmes, Ian Gibbons
-
Publication number: 20140030291Abstract: New influenza donor strains for the production of reassortant influenza A viruses are provided.Type: ApplicationFiled: June 3, 2013Publication date: January 30, 2014Applicant: Novartis AGInventors: Pirada SUPHAPHIPHAT, Peter MASON, Bjoern KEINER, Philip DORMITZER, Heidi TRUSHEIM
-
Publication number: 20140023680Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: September 25, 2013Publication date: January 23, 2014Applicant: MEDIMMUNE, LLCInventors: Chin-Fen YANG, George KEMBLE, Chongguang LIU
-
Patent number: 8613935Abstract: Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.Type: GrantFiled: February 3, 2010Date of Patent: December 24, 2013Assignee: Medimmune, LLCInventors: Hong Jin, Xing Cheng, Kanta Subbarao
-
Patent number: 8597661Abstract: Attenuated, neuraminidase deficient influenza virus, and compositions and methods to prepare that virus, are provided.Type: GrantFiled: May 1, 2008Date of Patent: December 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Masato Hatta
-
Patent number: RE44916Abstract: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1, NS1, PA, PB1, and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition.Type: GrantFiled: November 29, 2012Date of Patent: May 27, 2014Assignee: Iowa State University Research Foundation, Inc.Inventors: Kyoung-Jin Yoon, Vickie Cooper